Skip to main content
Peter MacCallum Cancer Centre
  • Donate
  • Location
  • Search
  • English
  • Easy English
  • العَرَبِيَّة Arabic
  • 中文 Chinese
  • Eλληνικά Greek
  • हिन्दी Hindi
  • Italiano Italian
  • Tagalog Tagalog
  • Türkçe Turkish
  • Tiếng Việt Vietnamese
  • About
  • Profiles
  • Careers
  • Education
  • News
  • Events
  • Get involved
  • Contact
  • Cancer types
    • Breast
    • Upper Gastrointestinal
    • Lower Gastrointestinal
    • Genitourinary Oncology
    • Gynae-oncology
    • Clinical Haematology
    • Head & neck
    • Lung
    • Melanoma & Skin
    • Neuro-oncology
    • Paediatric
    • Sarcoma
    • Cancer of unknown primary
  • Our services
    • Diagnosis & investigations
    • Treatment
    • Support services
    • Cancer information & resources
  • Coming to Peter Mac
    • Melbourne
    • Bendigo
    • Box Hill
    • Moorabbin
    • Sunshine
    • Telehealth
  • Research & discovery
    • Clinical research
    • Research laboratories
    • CoE Cellular Immunotherapy
    • Core facilities
    • ProsTIC
    • Research cohort studies
    • Research programs
    • Doing research with us
    • Commercialisation, partnerships and industry engagement
    • Publications
    • Research strategy
    • Education in research
    • Biomedical Animation
    • National Particle Therapy Symposium
    • Use your cancer experience to help guide research
  • Clinical Trial Care
    • Patients and Families
    • Health Professionals
    • Clinical Trial Sponsors
  1. Home
  2. Profiles
  3. Dr Michael Dickinson
Haematologist and Disease Group Lead: Aggressive Lymphoma

Dr Michael Dickinson

Aggressive lymphoma, myelodysplastic syndromes and AML, myeloma and early phase clinical trials

Biography

Michael Dickinson is the Lead of the Aggressive Lymphoma disease group within Clinical Haematology at Peter MacCallum Cancer Centre and Royal Melbourne Hospital.   He specialises as a principal investigator in phase I/II clinical trials of new anticancer drugs with a current focus on Aggressive Lymphomas and novel immunotherapies, but with experience across a breadth of haematological malignancies. His investigator-initiated studies have focused on the role of epigenetic modifiers in haematological malignancies,  eltrombopag as a supportive care agent in MDS/AML, and new CART therapies.  Michael's clinical research includes industry and investigator-led trials in aggressive lymphoma, phase 1 studies, and CART trials.

Michael prides himself on providing thorough and personal care to his patients throughout their cancer journey.

His current focus is:

1. The continuous improvement of the  lymphoma assessment service for patients with a new diagnosis of lymphoma or a lump for investigation; delivering best in the country diagnosis and staging evaluation in collaboration with Australia's leading haematopathology and molecular pathology centre, and with PET-centre physicians with a special interest in lymphoma.

2. Providing the best options for patients where standard treatments fail: Australia's largest and most comprehensive trials programme for patients with relapsed or treatment -refractory lymphoma.  Our early phase trial pipeline allows patients the best opportunity to harness new targeted treatments for cell signalling in lymphoma, and immunotherapies. At Peter Mac, our special expertise is in the development of the BCL-2 inhibitors (eg venetoclax),  epigenetic therapies, T-cell activating medications, and CART.

3. Providing new treatment options for patients with T-cell lymphoma.

4. Building our CART programme, both as a standard of care (if public funding is approved) and also providing CART trial options for patients with lymphoma.

5. Providing a training environment for tomorrow's experts. 

Related Links

Haematology
Aggressive Lymphoma
Acute Leukemia and Myelodysplasia
Myeloma and Autologous Stem Cell Transplantation

Michael Dickinson's Twitter Feed (Not A Peter Mac Feed)

Recent Press:

Sydney Morning Herald and The Age: 'Revolutionary' cancer drug using genetically modified cells approved

Sydney Morning Herald and The Age: Life at the cancer coalface: "My Place" Column by Hannie Rayson

2GB Ray Hadley Show: TGA Approval of CART tisagenlecleucel; Interview with John Stanley on the Ray Hadley Show

The Project: TGA approves CAR-T

Awards

2013: Julie Borschmann Research Fellow, University of Melbourne

2018: Peter MacCallum Cancer Centre Clinical Research Fellowship


 

Qualifications

MBBS (Hons), D.Med Sci, FRACP, FRCPA

Haematologist and Disease Group Lead: Aggressive Lymphoma

Dr Michael Dickinson

Aggressive lymphoma, myelodysplastic syndromes and AML, myeloma and early phase clinical trials

Phone
(03) 8559 7858 (PA) (Also contact the Lymphoma patient navigator
Fax
(03) 86720774 (Direct to email)

Peter MacCallum Cancer Centre

  • Victorian Comprehensive Cancer Centre building
    305 Grattan Street
    Melbourne VIC 3000
    Australia
    Peter MacCallum Cancer Centre
  • (03) 8559 5000 (In an emergency, call 000)
  • (03) 8559 7379 (Main fax)
  • (03) 8559 7371 (Referrals fax)
  • Locations
    • Melbourne
    • Bendigo
    • Box Hill
    • Moorabbin
    • Sunshine
  • About us
    • Get involved
    • Upcoming events
    • Partnerships
    • Patient charter
  • Cancer types
  • Cancer services
    • Diagnosis & investigations
    • Treatments
    • Cancer info & resources
  • Refer your patient
  • Peter MacCallum Cancer Foundation
  • Australian Cancer Survivorship Centre
  • Research & discovery
    • Clinical research & trials
    • Research cohort studies
    • Research labs
  • Careers
  • Education

Our Community

  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Contact us
Comments & feedback

The Peter MacCallum Cancer Centre acknowledges the traditional owners of the land on which our five sites are located throughout Victoria. We recognise their strength and resilience and pay our respects to their Elders past and present.

Languages
Auslan
Interpreter
Site by Icon Agency
  • Privacy policy
  • Terms & Conditions
  • Intranet